These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 28768964)

  • 21. A 12-month prospective real-life study of opicapone efficacy and tolerability in Emirati and non-White subjects with Parkinson's disease based in United Arab Emirates.
    Metta V; Ibrahim H; Muralidharan N; Rodriguez K; Masagnay T; Mohan J; Lacsina A; Ahmed A; Benamer HTS; Chung-Faye G; Mrudula R; Falup-Pecurariu C; Rodriguez-Blazquez C; Borgohain R; Goyal V; Bhattacharya K; Chaudhuri KR
    J Neural Transm (Vienna); 2024 Jan; 131(1):25-30. PubMed ID: 37798410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Entacapone reduces cortical activation in Parkinson's disease with wearing-off: a f-MRI study.
    Tambasco N; Muti M; Chiarini P; Tarducci R; Caproni S; Castrioto A; Nigro P; Parnetti L; Floridi P; Rossi A; Calabresi P
    PLoS One; 2014; 9(5):e96806. PubMed ID: 24830331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
    Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
    Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early DEtection of wEaring off in Parkinson disease: the DEEP study.
    Stocchi F; Antonini A; Barone P; Tinazzi M; Zappia M; Onofrj M; Ruggieri S; Morgante L; Bonuccelli U; Lopiano L; Pramstaller P; Albanese A; Attar M; Posocco V; Colombo D; Abbruzzese G;
    Parkinsonism Relat Disord; 2014 Feb; 20(2):204-11. PubMed ID: 24275586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levodopa induced motor complications in Thai Parkinson's disease patients.
    Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
    J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
    Talati R; Reinhart K; Baker W; White CM; Coleman CI
    Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Müller T
    Drugs; 2015 Feb; 75(2):157-74. PubMed ID: 25559423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study].
    Litvinenko IV; Odinak MM; Mogil'naia VI; Sologub OS; Sakharovskaia AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(1):51-4. PubMed ID: 19156087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone.
    Fung VS; Herawati L; Wan Y; ;
    Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease.
    Hattori N; Takeda A; Takeda S; Nishimura A; Nakaya R; Mochizuki H; Nagai M; Takahashi R
    J Neural Transm (Vienna); 2019 Mar; 126(3):289-297. PubMed ID: 30635744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.
    Reichmann H; Emre M
    Expert Rev Neurother; 2012 Feb; 12(2):119-31. PubMed ID: 22288667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wearing off: A complex phenomenon often poorly recognized in Parkinson's disease. A study with the WOQ-19 questionnaire.
    Pistacchi M; Gioulis M; Sanson F; Marsala SZ
    Neurol India; 2017; 65(6):1271-1279. PubMed ID: 29133700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levodopa fractionation in Parkinson's disease.
    Nyholm D; Stepien V
    J Parkinsons Dis; 2014; 4(1):89-96. PubMed ID: 24398654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study.
    Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H
    BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Entacapone in the treatment of Parkinson's disease.
    Schrag A
    Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
    Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
    Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.